Viking Therapeutics Secures Long-Term Manufacturing Agreement with CordenPharma for VK2735 Program
Viking Therapeutics, a clinical-stage biopharmaceutical company, recently announced a significant manufacturing agreement with CordenPharma, a leading contract development and manufacturing organization (CDMO). This multi-year deal covers the active pharmaceutical ingredient (API) and final finished product supply for Viking’s VK2735 program, which is being developed for the treatment of obesity.
Securing Dedicated Capacity for VK2735
Under this agreement, Viking will secure dedicated capacity for the production of both subcutaneous and oral forms of VK2735. The API supply will ensure that Viking has a consistent and reliable source of the active ingredient needed to manufacture its potential blockbuster drug. The final finished product supply will enable Viking to deliver its drug in both forms to meet the demands of a potential multi-billion-dollar annual market.
Dedicated Capacity for Autoinjector, Vial/Syringe Supply
Moreover, the deal includes dedicated fill/finish capacity for 100 million annual autoinjector supplies and an additional 100 million annual vial/syringe supplies. This capacity expansion will enable Viking to meet the diverse needs of its customer base, ensuring that it can provide its drug in various forms to cater to different patient preferences and healthcare provider requirements.
Prepayments Totaling $150 Million
Viking will make prepayments totaling $150 million between 2025 and 2028 to secure this long-term capacity. These prepayments will help Viking manage its cash flow and ensure a smooth supply chain for its VK2735 program. The payments will be made according to a schedule agreed upon by both parties, providing Viking with predictable and consistent costs.
Impact on Individuals
For individuals struggling with obesity, this agreement is a potential game-changer. Viking’s VK2735 program holds promise in addressing the complex metabolic and endocrine disorders that contribute to obesity. With this long-term manufacturing agreement in place, Viking can focus on bringing its drug to market more efficiently and effectively, ultimately providing a new treatment option for those in need.
Impact on the World
On a global scale, this agreement signifies a significant investment in the development and production of potential life-changing treatments for obesity. Obesity is a growing health concern worldwide, and the need for effective treatments is increasingly urgent. With this collaboration between Viking and CordenPharma, the world may soon have a new tool to combat obesity and improve the lives of millions.
Conclusion
Viking Therapeutics’ long-term manufacturing agreement with CordenPharma marks an essential step forward in the development and commercialization of its VK2735 program for obesity. By securing dedicated capacity for both API and finished product supply, Viking can ensure a reliable and consistent source of its drug, positioning itself to tap into a multi-billion-dollar annual market opportunity. This collaboration not only benefits Viking but also has the potential to make a significant impact on individuals struggling with obesity and the world as a whole by providing a new and potentially life-changing treatment option.
- Viking Therapeutics signs a multi-year manufacturing agreement with CordenPharma
- The agreement covers API and final finished product supply for VK2735 program
- Viking secures dedicated capacity for subcutaneous and oral forms of VK2735
- Dedicated fill/finish capacity for 100 million annual autoinjector and 100 million annual vial/syringe supplies
- Viking to make prepayments totaling $150 million between 2025 and 2028
- Potential game-changer for individuals with obesity and the world
